Please Wait
Applying Filters...
menu
    • menu
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

    Stock Recap
    #PipelineProspector

    Menu

    Inclisiran

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 700,271Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    31/10/2025 ST Pharma
    South Korea
    		 Novartis Korea Co., Ltd. Su196-29-ND inclisiran sodium 2024-06-20 ST Pharm Co., Ltd. South Korea 171 Haean-ro, Danwon-gu, Ansan-si, Gyeonggi-do